ArticleAsian Pacific journal of cancer prevention : APJCP2025
m5C-Related Regulators Define Tumor Microenvironment and Predict Prognosis in Hepatocellular Carcinoma.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is a highly lethal cancer and a leading cause of cancer-related deaths globally. RNA 5-methylcytosine (m5C) modification plays a vital role in epigenetic regulation, yet its impact on prognosis and the tumor immune microenvironment (TIME) in HCC remains unclear. MATERIALS AND
methodsRNA sequencing and clinical data were obtained from the Cancer Genome Atlas (TCGA) database. We applied an unsupervised clustering algorithm for the cluster analysis of m5C RNA methylation regulators, and then performed survival analyses to determine the best prognosis for HCC samples. Univariate and multivariate Cox regression analyses were conducted to construct a prognostic model. HCC patients were classified into high- and low-risk groups based on risk scores. Model performance was evaluated using ROC curves and validated with the ICGC cohort. Immune infiltration, clinicopathological features, and functional enrichment analyses were also performed.
resultWe analyzed the differential expression patterns of the m5C-related regulators between HCC and normal tissue samples. Based on consensus clustering of these regulators, three distinct molecular subgroups were identified, each associated with differences in patient survival and immune cell infiltration. Furthermore, we developed a prognostic signature comprising NSUN3, NSUN5, and YBX1, and stratified HCC patients into low- and high-risk groups. Patients in the low-risk group exhibited significantly better overall survival (OS) than those in the high-risk group. The robustness of this risk model was validated using the ICGC database. When integrated with clinicopathological characteristics, the risk score emerged as an independent prognostic factor. Additionally, we performed functional annotation and enrichment analyses based on differentially expressed genes (DEGs) between the two risk subgroups to explore potential underlying biological mechanisms.
conclusionOur study revealed the potential roles of these m5C-related regulators in TIME and identified their prognosis value and therapeutic potential for HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.